Goetze, T. O., Vogel, A., Gonzalez-Carmona, M. A., Habibzada, T., Reinecke, J., Adler, M., Pink, D., Ettrich, T. J., Roderburg, C., Pession, U., Saborowski, A. L., Boemmel, F. V., Wehler, T., Koehne, C., Schaaf, M., Sookthai, D., Eickhoff, R., Pons, M., Al-Batran, S., Modest, D. P. (2025). ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer—The IKF/AIO-ADJUBIL trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4132